ZVI FUKS, MD
Radiology at York Ave, New York, NY

License number

New York 157760

Organization information

See more information about ZVI FUKS at bizstanding.com

Memorial Sloan Kettering - Zvi Fuks MD

1275 York Ave #SM1, New York, NY 10065

Categories:

Oncology Physicians & Surgeons, Radiology Physicians & Surgeons

Phone:

(212) 639-2000 (Phone)

Professional information

See more information about ZVI FUKS at trustoria.com

Zvi Fuks, New York NY

Specialties:

Radiologist

Address:

1275 York Ave, New York, NY 10065
633 3Rd Ave, New York, NY 10017

Education:

Hadassah Medical School - Doctor of Medicine

Board certifications:

American Board of Radiology Certification in Therapeutic Radiology (Radiology)

Dr. Zvi Fuks, New York NY - MD (Doctor of Medicine)

Specialties:

Radiology, Therapeutic Radiology

Address:

MEMORIAL RADIATION ONCOLOGY GROUP
1275 York Ave, New York 10065
(800) 525-2225 (Phone)

Certifications:

Therapeutic Radiology

Awards:

Healthgrades Honor Roll

Languages:

English

Hospitals:

MEMORIAL RADIATION ONCOLOGY GROUP
1275 York Ave, New York 10065
Memorial Sloan - Kettering Cancer Center
1275 York Ave, New York 10065

Education:

Medical School
Hadassah Medical School, The Hebrew University Of Jerusalem
Graduated: 1960

Heparanase Derived From Human Sk-Hep-1 Cell Line

US Patent:

5362641, Nov 8, 1994

Filed:

Jan 8, 1992

Appl. No.:

7/768900

Inventors:

Zvi Fuks - New York NY
Israel Vlodavsky - Gilo, IL

Assignee:

Hadassah Medical Organization Kiryat Hadassah - Jerusalem

International Classification:

C12N 926, C12N 924, C12N 942, C12N 914

US Classification:

435209

Abstract:

The present invention relates to a substantially purified heparanase obtained from the human SK-HEP-1 cell line and a method to purify the heparanase from a centrifuged dialyzed homogenate of the SK-HEP-1 cells or a cell culture medium containing the heparanase from the SK-HEP-1 cell line.

Method And Composition To Increase Radiation-Induced Tumor Therapeutic Effects

US Patent:

2012025, Oct 4, 2012

Filed:

Dec 7, 2010

Appl. No.:

13/513890

Inventors:

Richard N. Kolesnick - New York NY, US
Branka Stancevic - New York NY, US
Michel Sadelain - New York NY, US
Zvi Fuks - New York NY, US
Nira Varda-Bloom - Hod-Hasharon, IL
Dror Harats - Ramat-Gan, IL

Assignee:

MEMORIAL SLOAN-KETTERING CANCER CENTER ("MSKCC") - New York NY

International Classification:

C12N 15/55, A61K 31/7088, A61P 35/00, C12N 15/63

US Classification:

514 44 R, 536 232, 4353201

Abstract:

Disclosed herein are methods and compositions for treating cancer by increasing radiation-induced damage to cancer without increasing radiation-induced side effects by increasing secretory ASMase levels specifically in tumor endothelium, and inducing apoptosis of tumor endothelial cells by treating the tumor with radiation. ASMase levels are increased in tumor endothelium by administration of a recombinant DNA construct comprising a region coding for a functional ASMase linked to particular transcriptional regulatory sequences that confer tissue-specific expression of ASMase.

Method Of Killing Sarcoma Cells Using Fludarabine Phosphate And Ionizing Radiation

US Patent:

5081110, Jan 14, 1992

Filed:

Dec 13, 1988

Appl. No.:

7/283734

Inventors:

Jae H. Kim - Tenafly NJ
Alan A. Alfieri - Garden City NY
Sang H. Kim - Flushing NY
Zvi Fuks - New York NY

Assignee:

Sloan-Kettering Institute For Cancer Research - New York NY

International Classification:

A61K 3170, A61W 500

US Classification:

514 47

Abstract:

This invention provides a method of killing sarcoma cells in a patient by administering to the patient an effective amount of fludarabine phosphate effective to inhibit the repair of potentially lethal damage to the sarcoma cells and exposing the patient to an effective amount of ionizing radiation, effective to kill the sarcoma tumor cells in the patient.